Zura Bio FY2025 net loss $99.4M; raised $144M in Feb 2026; tibulizumab data on track

Zura Bio Ltd

Net loss attributable to Class A shareholders $99.4M ($1.06/share) vs $45.4M ($0.60) in 2024.
Cash and equivalents $109.4M at Dec 31, 2025; Feb 2026 offering raised ~$144M gross.
R&D expenses $42.1M, up 73% YoY, driven by Phase 2 tibulizumab programs.
Phase 2 TibuSHIELD (HS) topline data expected Q4 2026; TibuSURE (SSc) data H1 2027.
Appointed Sandeep Kulkarni as CEO in Jan 2026; added two board members in Feb 2026.

item 2.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-26-032077
form_type: 8-K
ticker: ZURA
cik: 0001855644
company_name: Zura Bio Ltd
filed_at: 2026-03-19T23:59:59+00:00
discovered_at: 2026-05-14T18:02:36.568478+00:00
generated_at: 2026-05-15T09:41:44.412924+00:00
sec_items: ["2.02", "7.01", "9.01"]
event_type: earnings
sentiment: negative
materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-26-032077
json_url: https://secwatch.observer/filing/0001104659-26-032077.json
markdown_url: https://secwatch.observer/filing/0001104659-26-032077.md
text_url: https://secwatch.observer/filing/0001104659-26-032077.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1855644/000110465926032077/0001104659-26-032077-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1855644/000110465926032077/tm269296d1_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001104659-26-032077

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.